At the same time as researchers search for biomarkers to forecast ketamine response, clinicians find them selves with a conundrum: Which patients need to start with IV ketamine, and which with Spravato? And exactly how do The 2 compare head to head in true response to treatment? Mount Sinai released https://camillau233ynb1.newbigblog.com/profile